このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Opthea マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Fred Guerard

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	2.2yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Fred Guerard (51 yo)

less than a year

在職期間

Dr. Frederic Guerard, Pharm. D. M.S. also known as Fred, is Chief Executive Officer of Opthea Limited from October 27, 2023. He has been Independent Director at Lenz Therapeutics, Inc. since 2021.He is a...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Megan Baldwin	Founder	no data	US$1.57m	0.018% $ 72.3k
Judith Robertson	Chief Commercial Officer	2.4yrs	US$856.83k	データなし
Karen Adams	VP of Finance & Company Secretary	3yrs	US$507.60k	データなし
Frederic Guerard	Chief Executive Officer	less than a year	データなし	データなし
Peter Lang	Chief Financial Officer	less than a year	データなし	データなし
Sarika Gulhar	Executive Director of Human Resources	1.4yrs	データなし	データなし
Michael Gerometta	Head of Chemistry	15.5yrs	US$197.04k	データなし
Bruno Gagnon	Senior Vice President of Global Clinical Operations	1.8yrs	データなし	データなし
Kenneth Sall	Chief Medical Officer	less than a year	データなし	データなし
Fang Li	Senior Vice President of Regulatory Affairs	less than a year	データなし	データなし
Julie Clark	Senior Vice President of Clinical Development	less than a year	データなし	データなし
Arshad Khanani	Chief Medical Advisor	less than a year	データなし	データなし

0.9yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: OPTの経営陣は経験豊富とはみなされません ( 0.9年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Megan Baldwin	Founder	no data	US$1.57m	0.018% $ 72.3k
Jeremy Levin	Chairperson	3.7yrs	US$425.47k	0.0029% $ 11.7k
Jason Slakter	Member of Clinical Advisory Board	no data	データなし	データなし
Quinton Oswald	Independence Non-Executive Director	2.2yrs	US$202.36k	データなし
Julia Haller	Independent Non-Executive Director	3yrs	US$327.41k	データなし
Lawrence Gozlan	Independent Non-Executive Director	3.9yrs	US$724.31k	0.17% $ 694.6k
Sujal Shah	Non-Executive Director	less than a year	データなし	データなし
Anshul Thakral	Non-Executive Director	less than a year	US$3.16k	データなし
Charles Wykoff	Member of Clinical Advisory Board	no data	データなし	データなし
Susan Orr	Independent Non-Executive Director	2.2yrs	US$206.20k	データなし
Tim Jackson	Member of Clinical Advisory Board	no data	データなし	データなし

2.2yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: OPTの取締役会は経験豊富ではない ( 2.2年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Opthea マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Less than half of directors are independent

Opthea Limited Announces Board Changes

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Recent updates

New major risk - Shareholder dilution

Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

Price target increased by 14% to AU$0.90

Consensus revenue estimates decrease by 96%, EPS upgraded

New major risk - Financial position

Consensus revenue estimates increase by 13%

New minor risk - Profitability

Consensus revenue estimates decrease by 14%

Less than half of directors are independent

Consensus EPS estimates fall by 11%

Opthea Limited Announces Board Changes

Consensus revenue estimates fall by 94%

Consensus revenue estimates decrease by 14%, EPS upgraded

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Consensus revenue estimates decrease by 94%

Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Opthea Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 94%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 9.0% to AU$1.55

Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited Announces Executive Changes

Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board

Consensus revenue estimates increase by 12%

Consensus EPS estimates upgraded to US$0.25 loss

Consensus EPS estimates fall by 44%

First half 2023 earnings released: US$0.17 loss per share (vs US$0.11 loss in 1H 2022)

Consensus revenue estimates increase by 12%

Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology

Consensus forecasts updated

Independent Non-Executive Director exercised options to buy AU$173k worth of stock.

High number of new directors

Opthea Limited Appoints Timothy E. Morris as Chief Financial Officer

Opthea Limited, Annual General Meeting, Nov 16, 2022

Consensus forecasts updated

Full year 2022 earnings: EPS and revenues miss analyst expectations

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea Limited, Annual General Meeting, Sep 26, 2022

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?

High number of new directors

Opthea Limited Announces Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy Presented at ARVO 2022

High number of new directors

Opthea Limited Announces Board Appointments

Consensus forecasts updated

Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Announces Data for OPT-302 in Patients with PVC

We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely

This Is Why Opthea Limited's (ASX:OPT) CEO Compensation Looks Appropriate

Price target decreased to AU$2.95

Full year 2021 earnings released: US$0.14 loss per share (vs US$0.043 loss in FY 2020)

Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation

Opthea Limited Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada

High number of new directors

Opthea's OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration

Price target decreased to AU$4.24

Opthea Limited Treats First Patient in Phase 3 Trials of OPT-302

Independent Non-Executive Director exercised options to buy AU$1.1m worth of stock.

We Think Opthea (ASX:OPT) Can Afford To Drive Business Growth

Opthea Limited Finalizes Study Designs and Start-Up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.03 loss in 1H 2020)

New 90-day low: AU$1.75

マネジメント基準チェック /04